Pancreatic Cancer

An artificial intelligence model may help move patients into treatment pathways for pancreatic cancer quicker, says Russell C. Langan, MD, FACS, FSSO.

In an era where medical records are digitalized, artificial intelligence has the potential to identify patterns that can locate at-risk patients with pancreatic cancer.

The rare nature of pancreatic cancer makes identifying it difficult, but progress towards earlier identification is being made, according to Brian M. Wolpin, MD, MPH.

Zenocutuzumab is now approved for patients with NRG1 fusion-positive NSCLC or pancreatic adenocarcinoma.

The relatively inexpensive nature of liquid biopsy may allow for more frequent screening among individuals who are at risk of developing pancreatic cancer.

There are certain markers that can point to a greater risk of pancreatic cancer like BRCA1/2, and diabetes, according to Brian M. Wolpin, MD.

The pancreatic cancer field may not be far from seeing the use of non-invasive blood tests in pancreatic cancer, said Ajay Goel, PhD, AGAF.

Tumor treating fields with chemotherapy improved overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma.

Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.

The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

The key to the future of pancreatic cancer treatment is immunotherapy, according to Gregory L. Beatty, MD, PhD.

Bolstering the effectiveness of T cells and the further implementation of AI can both yield positive results in the future of pancreatic cancer treatment.

Shubham Pant, MD, MBBS, highlights how pan-RAS inhibitors, RAS-directed vaccines, and biomarker testing can improve outcomes in pancreatic cancer.

Immunohistochemistry presents a solution to the obstacles that the different identified cellular neighborhoods in pancreatic tumors create.

Researchers are trying to figure out how to create immune memory with immunotherapy in patients with pancreatic cancer.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

The incorporation of palliative care specific to mental health services and therapy remains underutilized in the care of patients with pancreatic cancer.

A nurse practitioner gives a closer look into the risk factors, diagnosis, adverse effects, and future treatments associated with pancreatic cancer.

It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.

Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.

The 18-month overall survival rate with the mitazalimab combination in OPTIMIZE-1 exceeds a historical rate achieved with FOLFIRINOX alone.

The updated Prescription Drug User Fee Act date for zenocutuzumab in these indications is February 4, 2025.

Study data show that no patient with a response required opioids after a 24-hour post-procedure follow-up.

Results from the CANFOUR trial of combining nadunolimab with chemotherapy appear to prolong overall survival among those with advanced or metastatic PDAC.